Publication Name	World Journal of Diabetes
Manuscript ID	94151
Country	Kuwait

Received	2024-03-12 11:35
Peer-Review Started	2024-03-12 11:35
To Make the First Decision
Return for Revision	2024-05-09 07:20
Revised	2024-05-14 10:44
Second Decision	2024-06-12 02:41
Accepted by Journal Editor-in-Chief
Accepted by Executive Editor-in-Chief	2024-06-12 07:53
Articles in Press	2024-06-12 07:53
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript	2024-06-28 07:46
Publish the Manuscript Online	2024-07-26 06:56

ISSN	1948-9358 (online)
Open Access	This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/
Copyright	© The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Cardiac & Cardiovascular Systems
Manuscript Type	Editorial
Article Title	Teneligliptin: A potential therapeutic approach for diabetic cardiomyopathy
Manuscript Source	Invited Manuscript
All Author List	Ashraf Al Madhoun
ORCID	Author(s) ORCID Number Ashraf Al Madhoun http://orcid.org/0000-0001-8593-3878
Funding Agency and Grant Number	Funding Agency Grant Number Kuwait Foundation for the Advancement of Sciences and Dasman Diabetes Institute RACB-2021-007
Corresponding Author	Ashraf Al Madhoun, PhD, Academic Editor, Research Scientist, Senior Scientist, Department of Genetics and Bioinformatics, Dasman Diabetes Institute, Jassim AlBahar Street, Dasman 15400, Kuwait. ashraf.madhoun@dasmaninstitute.org
Key Words	Teneligliptin; Diabetes mellitus; NOD-like receptor protein 3 inflammasome; Inflammation, Cardiomyopathy
Core Tip	Zhang et al provided evidences that teneligliptin mitigated diabetic cardiomyopathy. The authors also clarified the undelaying molecular mechanisms, showing that teneligliptin inhibits NADPH oxidase 4, NOD-like receptor protein 3 inflammasome and activates activated protein kinase to maintain myocyte homeostasis. Researchers are encouraged to implement similar studies on human to delineate the precise mechanism by which teneligliptin influences activated protein kinase and NOD-like receptor protein 3 signaling.
Publish Date	2024-07-26 06:56
Citation	<p>Al Madhoun A. Teneligliptin: A potential therapeutic approach for diabetic cardiomyopathy. <i>World J Diabetes</i> 2024; 15(8): 1654-1658</p>
URL	https://www.wjgnet.com/1948-9358/full/v15/i8/1654.htm
DOI	https://dx.doi.org/10.4239/wjd.v15.i8.1654

Full Article (PDF)	WJD-15-1654-with-cover.pdf
Manuscript File	94151_Auto_Edited-YJP.docx
Answering Reviewers	94151-answering-reviewers.pdf
Audio Core Tip	94151-audio.mp3
Conflict-of-Interest Disclosure Form	94151-conflict-of-interest-statement.pdf
Copyright License Agreement	94151-copyright-assignment.pdf
Approved Grant Application Form(s) or Funding Agency Copy of any Approval Document(s)	94151-foundation-statement.pdf
Non-Native Speakers of English Editing Certificate	94151-non-native-speakers.pdf
Peer-review Report	94151-peer-reviews.pdf
Scientific Misconduct Check	94151-scientific-misconduct-check.png
Scientific Editor Work List	94151-scientific-editor-work-list.pdf
CrossCheck Report	94151-crosscheck-report.pdf